Skip to Content

Ixiaro Approval History

FDA Approved: Yes (First approved March 30, 2009)
Brand name: Ixiaro
Generic name: Japanese Encephalitis Virus Vaccine, Inactivated, Adsorbed
Company: Intercell AG
Treatment for: Japanese Encephalitis Virus Prophylaxis

Ixiaro (Japanese Encephalitis Virus Vaccine, Inactivated, Adsorbed) is a purified, inactivated product for active immunization against viral infections of Japanese Encephalitis.

Development History and FDA Approval Process for Ixiaro

DateArticle
Oct  5, 2018Approval FDA Approves Accelerated 7-Day Vaccine Dosing Schedule for Ixiaro
Mar 31, 2009Approval Intercell Announces FDA Approval of Ixiaro, a Novel Vaccine to Prevent Japanese Encephalitis
Oct 21, 2008Intercell making strides towards imminent approval of its Japanese Encephalitis vaccine in the United States –Approvals in United States, Europe and Australia remain on track for 2008

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide